Knowledge patient


An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study


Cover of 1st issue of PMSJ (later BMJ)Image via Wikipedia

BMJ. 2010 May 13;340:c2442. doi: 10.1136/bmj.c2442.

An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study.

Source

Centre for Statistics in Medicine, Wolfson College Annexe, University of Oxford, Oxford OX2 6UD. gary.collins@csm.ox.ac.uk

Abstract

OBJECTIVE:

To evaluate the performance of the QRISK2 score for predicting 10-year cardiovascular disease in an independent UK cohort of patients from general practice records and to compare it with the NICE version of the Framingham equation and QRISK1.

DESIGN:

Prospective cohort study to validate a cardiovascular risk score.

SETTING:

365 practices from United Kingdom contributing to The Health Improvement Network (THIN) database.

PARTICIPANTS:

1.58 million patients registered with a general practice between 1 January 1993 and 20 June 2008, aged 35-74 years (9.4 million person years) with 71 465 cardiovascular events.

MAIN OUTCOME MEASURES:

First diagnosis of cardiovascular disease (myocardial infarction, angina, coronary heart disease, stroke, and transient ischaemic stroke) recorded in general practice records.

RESULTS:

QRISK2 offered improved prediction of a patient’s 10-year risk of cardiovascular disease over the NICE version of the Framingham equation. Discrimination and calibration statistics were better with QRISK2. QRISK2 explained 33% of the variation in men and 40% for women, compared with 29% and 34% respectively for the NICE Framingham and 32% and 38% respectively for QRISK1. The incidence rate of cardiovascular events (per 1000 person years) among men in the high risk group was 27.8 (95% CI 27.4 to 28.2) with QRISK2, 21.9 (21.6 to 22.2) with NICE Framingham, and 24.8 (22.8 to 26.9) with QRISK1. Similarly, the incidence rate of cardiovascular events (per 1000 person years) among women in the high risk group was 24.3 (23.8 to 24.9) with QRISK2, 20.6 (20.1 to 21.0) with NICE Framingham, and 21.8 (18.9 to 24.6) with QRISK1.

CONCLUSIONS:

QRISK2 is more accurate in identifying a high risk population for cardiovascular disease in the United Kingdom than the NICE version of the Framingham equation. Differences in performance between QRISK2 and QRISK1 were marginal.

Enhanced by Zemanta

Reconocimiento a Julio Ceitlin


Un justo reconocimiento a la labor y la historia de Julio Ceitlin. Uno de los hombres fundadores de la medicina familiar en iberoamérica. Mis felicitaciones a Julio, y mi agradecimiento por todo lo que me enseñó. El es uno de mis pocos maestros.

Dear Julio

I hope this message finds you well.

On behalf of the leadership of The College of Family Physicians of Canada ( CFPC) , I am pleased to share the news with you that you have been selected to receive Honorary Membership in the CFPC. This is an honour bestowed each year to a small number of outstanding individuals who have contributed significantly to our College or the discipline of family medicine and family practice and/or the health and well- being of the population in Canada or internationally. Your leadership of the specialty of family medicine in South America and the impact of your work globally, including of course your interest in ,communication with and recognition of the challenges we face in family medicine in Canada have long earned the respect and admiration of your friends and colleagues in our College

The award will be presented during our Convocation and Awards presentations on the final evening of Family Medicine Forum 2011 being held at the Palais de Congres in Montreal Quebec on Saturday November 5th 2011.

The award includes complimentary registration to Family Medicine Forum 2011 being held from Nov 3-5 in Montreal as well as up to $1500.00 to offset travel and other expenses .Recipients of Honorary Membership may append the special designation MCFP (Hon) following their names .

My sincere congratulations, Julio on having being named to receive this award. We look forward to your being able to join us in Montreal for this special presentation.

Sincerely

Cal

Calvin Gutkin, MD, CCFP (EM), FCFP

Executive Director & Chief Executive Officer

The College of Family Physicians of Canada

Phone: 800-387-6197 x 237

905-629-0900 x 237

Fax: 905-629-0893

Email: cgutkin@cfpc.ca

Website: http://www.cfpc.ca

Enhanced by Zemanta

Case Files Familly Medicine 2nd. ed.


Password: http://medicalbooks4everyone.blogspot.com/